{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-001760","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.791035+00:00","generated_at":"2026-06-27T21:01:39.358551+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Fulcrum Therapeutics appoints Esther Rajavelu as CFO and Treasurer","bullets":["Esther Rajavelu appointed CFO and Treasurer effective Jan 3, 2022; Peter Thomson ceases as principal financial officer.","Rajavelu receives $435,000 annual base salary, $150,000 signing bonus, and 200,000 stock option at $17.82/share.","Option vests 25% on first anniversary, then 6.25% quarterly over 12 quarters.","Rajavelu has ~20 years life sciences experience including UBS, Oppenheimer, Deutsche Bank, and EY Capital.","Press release highlights two disease-modifying programs (losmapimod for FSHD, FTX-6058 for sickle cell)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-001760","json":"https://secwatch.observer/filing/0001193125-22-001760.json","markdown":"https://secwatch.observer/filing/0001193125-22-001760.md","text":"https://secwatch.observer/filing/0001193125-22-001760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/d237013d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T21:01:39.358551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d307612f6","claim":"Peter Thomson changed role as Principal Financial Officer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"As a result of Ms. Rajavelu’s appointment, Peter Thomson, the Company’s Vice President, Finance and Accounting, will cease to serve as principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ec5b5a3503","claim":"Esther Rajavelu was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On January 3, 2022, the Board of Directors (the “Board”) of Fulcrum Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Treasurer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}